# Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

> **NCT06224257** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 41 (estimated)

## Conditions studied

- Relapsed/Refractory Large Granular T Lymphocytic Leukemia

## Interventions

- **DRUG:** Linperlisib

## Key facts

- **NCT ID:** NCT06224257
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-03
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06224257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06224257, "Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06224257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*